Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting
Hymenoptera venom hypersensitivity reaction affects about 3% of the general population and a higher percentage (14%–43%) in beekeepers. Bee venom immunotherapy (bVIT) is effective in reducing subsequent severe systemic reactions and has a significant beneficial effect on disease-specific quality of...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Indian Journal of Allergy Asthma and Immunology |
Subjects: | |
Online Access: | http://www.ijaai.in/article.asp?issn=0972-6691;year=2021;volume=35;issue=2;spage=94;epage=98;aulast=Kathuria |
_version_ | 1828268406055370752 |
---|---|
author | P C Kathuria Manisha Rai Ghulam Hassan |
author_facet | P C Kathuria Manisha Rai Ghulam Hassan |
author_sort | P C Kathuria |
collection | DOAJ |
description | Hymenoptera venom hypersensitivity reaction affects about 3% of the general population and a higher percentage (14%–43%) in beekeepers. Bee venom immunotherapy (bVIT) is effective in reducing subsequent severe systemic reactions and has a significant beneficial effect on disease-specific quality of life in both children and adults. In patients with a history of recurrent systemic anaphylactic reaction with bee venom, successful bVIT is difficult to achieve and can often lead to withdrawal of treatment. The combination of bVIT and omalizumab is a good option for these patients. Omalizumab is a humanized nonanaphylactogenic monoclonal anti-immunoglobulin (Ig) E antibody against the Cε3 domain of IgE to reduce the allergenicity, if combined with bVIT. We describe a successful treatment with combined omalizumab and bVIT in a case of recurrent anaphylaxis by honey bee sting hypersensitivity. Herein, subcutaneous omalizumab 150 mg was started 15 days before the initiation of bVIT and subsequently once a month for 30 months along with cluster doses of bVIT till the cumulative dose of 100 μg was achieved successfully. |
first_indexed | 2024-04-13T05:17:20Z |
format | Article |
id | doaj.art-417912fa5a3f43008316fe20bedf96ac |
institution | Directory Open Access Journal |
issn | 0972-6691 |
language | English |
last_indexed | 2024-04-13T05:17:20Z |
publishDate | 2021-01-01 |
publisher | Wolters Kluwer Medknow Publications |
record_format | Article |
series | Indian Journal of Allergy Asthma and Immunology |
spelling | doaj.art-417912fa5a3f43008316fe20bedf96ac2022-12-22T03:00:51ZengWolters Kluwer Medknow PublicationsIndian Journal of Allergy Asthma and Immunology0972-66912021-01-01352949810.4103/ijaai.ijaai_28_21Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee stingP C KathuriaManisha RaiGhulam HassanHymenoptera venom hypersensitivity reaction affects about 3% of the general population and a higher percentage (14%–43%) in beekeepers. Bee venom immunotherapy (bVIT) is effective in reducing subsequent severe systemic reactions and has a significant beneficial effect on disease-specific quality of life in both children and adults. In patients with a history of recurrent systemic anaphylactic reaction with bee venom, successful bVIT is difficult to achieve and can often lead to withdrawal of treatment. The combination of bVIT and omalizumab is a good option for these patients. Omalizumab is a humanized nonanaphylactogenic monoclonal anti-immunoglobulin (Ig) E antibody against the Cε3 domain of IgE to reduce the allergenicity, if combined with bVIT. We describe a successful treatment with combined omalizumab and bVIT in a case of recurrent anaphylaxis by honey bee sting hypersensitivity. Herein, subcutaneous omalizumab 150 mg was started 15 days before the initiation of bVIT and subsequently once a month for 30 months along with cluster doses of bVIT till the cumulative dose of 100 μg was achieved successfully.http://www.ijaai.in/article.asp?issn=0972-6691;year=2021;volume=35;issue=2;spage=94;epage=98;aulast=Kathuriabee venom allergyanaphylaxisvenominsect stinghymenopteravenom immunotherapybee venom immunotherapyomalizumab |
spellingShingle | P C Kathuria Manisha Rai Ghulam Hassan Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting Indian Journal of Allergy Asthma and Immunology bee venom allergy anaphylaxis venom insect sting hymenoptera venom immunotherapy bee venom immunotherapy omalizumab |
title | Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting |
title_full | Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting |
title_fullStr | Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting |
title_full_unstemmed | Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting |
title_short | Successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting |
title_sort | successful treatment with a combination of bee venom immunotherapy and omalizumab for recurrent anaphylaxis after honey bee sting |
topic | bee venom allergy anaphylaxis venom insect sting hymenoptera venom immunotherapy bee venom immunotherapy omalizumab |
url | http://www.ijaai.in/article.asp?issn=0972-6691;year=2021;volume=35;issue=2;spage=94;epage=98;aulast=Kathuria |
work_keys_str_mv | AT pckathuria successfultreatmentwithacombinationofbeevenomimmunotherapyandomalizumabforrecurrentanaphylaxisafterhoneybeesting AT manisharai successfultreatmentwithacombinationofbeevenomimmunotherapyandomalizumabforrecurrentanaphylaxisafterhoneybeesting AT ghulamhassan successfultreatmentwithacombinationofbeevenomimmunotherapyandomalizumabforrecurrentanaphylaxisafterhoneybeesting |